Document:

CAPITAL EXPENDITURE AND EQUIPMENT AGREEMENT

 Exhibit 10.39 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION. 
  
 CAPITAL
EXPENDITURE AND EQUIPMENT AGREEMENT 
 THIS CAPITAL EXPENDITURE AND EQUIPMENT AGREEMENT (this
“Agreement”) is effective as of December 19, 2011(the “Effective Date”) between 

POZEN INC., a corporation existing under the laws of the State of Delaware, located at 1414 Raleigh Road, Suite 400, Chapel Hill,
NC 27517 (“Pozen”) 
 - and - 

PATHEON PHARMACEUTICALS INC., 
 a corporation existing under the laws of the State of Delaware, located at 2110 East Galbraith Road, Cincinnati, OH 45237-1625 (“Patheon”) 

BACKGROUND 
 Pozen and Patheon are parties to a Master Pharmaceutical Development Agreement dated August 18, 2010 and are negotiating the terms of a Manufacturing Services Agreement (the “MSA”)
under which Patheon will perform certain manufacturing services (the “Services”) related to Pozen’s PA 325 Tablets (the “Product”). In order for Patheon to perform the Services under the MSA, certain capital
expenditures will be required for the purchase and installation of capital equipment and facility modifications at Patheon’s facility located at 2110 East Galbraith Road, Cincinnati, Ohio 45237-1625 (the “Facility”).

 AGREEMENT 
 NOW, THEREFORE, in consideration of the rights conferred and the obligations assumed herein, and intending to be legally bound, the parties hereby agree as follows: 

 

	1.	 Definitions 

 “Dedicated Equipment” means the items listed in that category on Schedule A. 
 “Facility Modifications” means the items listed in that category on Schedule A. 
 “Non-Dedicated Equipment” means the items listed in that category on Schedule A. 
 “Patheon Funded Capital” means the items listed in that category on Schedule A. 
 “Pozen Funded Capital” means the items listed in that category on Schedule A. 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
 -  2  - 
  
  

	2.	 Expenditures and Payment 

 The estimated cost ranges for the purchase and installation of the Pozen Funded Capital for the project are set forth in Schedule A. Notwithstanding any other provisions of this Agreement, the individual
amount of each item on Schedule A may be increased or decreased to reflect Patheon’s actual cost but the aggregate amount contributed by Pozen for the Dedicated Equipment, Non-Dedicated Equipment and Facility Modifications will not exceed $***
unless there are further modifications or changes in the processes or requirements for the Services or if the assumptions underlying the estimated costs change. If this occurs, the parties will agree on revised cost estimates and a revised maximum
aggregate amount to be contributed by Pozen. 
 Patheon has reviewed the capacity of its existing ***, which
will be used for Pozen and also for other Patheon clients, to determine if additional *** will be required to perform the Services for Pozen. Based on the current long range forecasts for the Product and for third party products, Patheon anticipates
being able to support most, if not all of the Pozen’s projected forecast for the Product using the existing *** If an additional *** is required to perform the Services, the cost for this ***, associated engineering and the Facility
Modifications shown in Schedule A will be provided by Pozen. If for some unforeseen reason, additional capacity beyond *** is required, the Parties will negotiate responsibility for the additional capital in good faith. 

Subject to these limitations, Patheon will inform Pozen in writing when the purchase of the Pozen Funded Capital is
necessary and Pozen will give written notice to Patheon to incur, on its behalf, pre-approved direct out of pocket costs for the Pozen Funded Capital as set forth in Schedule A. Patheon will give Pozen copies of third party invoices for these items
(where applicable) within 30 days after Patheon’s receipt thereof and will issue its invoice with respect to the items set forth in Schedule A to Pozen. Pozen will pay all amounts owing to Patheon within 30 days of the date of the Patheon
invoice to enable Patheon to pay all amounts owed under the third party invoices. 
  

	3.	 Patheon Use of Non-Dedicated Equipment and Facility Modifications 

Patheon may use the Non-Dedicated Equipment and Facility Modifications to manufacture products for third parties without
any compensation for this use owed to Pozen. Patheon will indemnify and hold Pozen, its affiliates and the directors, officers and employees of these entities and their successors and assigns harmless from any claims, actions, suits or proceedings
brought by a third party which arise out of or in connection with the use of the Non-Dedicated Equipment and Facility Modifications to manufacture third party product. 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
 -  3  - 
  
  

	4.	 Maintenance of Dedicated and Non-Dedicated Equipment 

 

	 	(a)	 Patheon will at its expense perform routine repairs, preventive maintenance, and calibration on the Dedicated Equipment and Non-Dedicated Equipment.
Patheon will have an annual aggregate limit on these costs of $***. Repair, maintenance, and calibration costs, including the cost of spare part purchases or equipment upgrades requested by Pozen that exceed this annual aggregate limit will be
invoiced to Pozen at Patheon’s actual cost. 

  

	 	(b)	 Patheon will give Pozen reasonable access during normal working hours for the inspection of the Pozen Funded Capital. 

 

	 	(c)	 Patheon shall not sell, assign, transfer, pledge, hypothecate, mortgage or dispose of, by gift or otherwise, whether voluntarily or by operation of
law, all or any part of the Dedicated Equipment. Patheon will keep the Dedicated Equipment free from encumbrances, liens, and interests of third parties. 

 

	 	(d)	 Patheon will notify Pozen if any accident, loss of or damage occurs to the Pozen Funded Capital. 

 

	 	(e)	 Patheon shall not transfer the Dedicated Equipment or Non-Dedicated Equipment out of the Facility without written prior notification to Pozen.

  

	5.	 Title and Risk of Loss of the Equipment and Facility Improvements 

The Dedicated Equipment will be owned by Pozen, which will be the sole legal and beneficial owner thereof. Title and risk
of loss to the Non-Dedicated Equipment and Facility Modifications will be with Patheon, which will be the sole legal and beneficial owner thereof. Patheon will at all time keep the Dedicated Equipment, Non-Dedicated Equipment and Facility
Modifications insured at replacement cost, and Patheon will replace any of these items that are lost, damaged or destroyed. 
  

	6.	 Term; Termination; Effect of Termination on Future Funding 

 

	 	(a)	 Term, Termination. 

 (i) This Agreement will commence on the Effective Date and, unless earlier terminated as set forth in this Section 6, will continue in effect until the expiration or termination of the MSA, including
any extensions thereof. 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
 -  4  - 
  
  

(ii) Either party at its sole option may terminate this Agreement upon written notice where the other party has failed
to remedy a material breach of any of its obligations under this Agreement within *** days following receipt of a written notice of the breach that expressly states in reasonable detail the nature of the breach. 

(iii) This Agreement will terminate automatically if the parties have not executed all of the documents comprising the
MSA by December 31, 2011, unless this date is extended by written agreement of the parties. 
  

	 	(b)	 Effect of Termination on Future Funding toward Pozen Capital Contributions. 

If this Agreement or the MSA is terminated by Pozen, Pozen’s obligation to further fund expenditures toward the
Pozen Funded Capital set forth in Schedule A of this Agreement will cease upon Patheon’s receipt of the notice of termination of this Agreement or the MSA, except for the cost of non-cancellable commitments toward the Pozen Funded Capital set
forth in Schedule A of this Agreement that are made by Patheon prior to receiving written notice of the termination. 
 If this Agreement or the MSA is terminated by Patheon, Pozen’s obligation to further fund expenditures toward the Pozen Funded Capital set forth in Schedule A of this Agreement will cease upon
receipt by Pozen of the notice of termination of this Agreement or the MSA except for the cost of non-cancellable commitments toward the Pozen Funded Capital set forth in Schedule A of this Agreement that are made by Patheon prior to providing
written notice of the termination. 
 If this Agreement terminates automatically due to failure of the parties
to enter into the MSA as set forth above in Section 6(a), Pozen’s obligation to fund expenditures toward the Pozen Funded Capital set forth in Schedule A of this Agreement will cease as of the automatic termination date except for the cost
of non-cancellable commitments toward the Pozen Funded Capital set forth in Schedule A of this Agreement that are made by Patheon under this Agreement prior to the automatic termination date. 

 

	 	(c)	 Dedicated Equipment Removal. 

 If this Agreement expires or is terminated for any reason, within 30 days of termination, Pozen will remove, or arrange to remove, from the Facility at its expense all Dedicated Equipment. 

 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] 
 -  5  - 
  
  

	7.	 General 

  

	 	(a)	 All monetary amounts are expressed in the lawful currency of the United States of America. 

 

	 	(b)	 This Agreement will be construed and enforced in accordance with the laws of the State of Delaware (without regard to principles of conflicts of
law). 

  

	 	(c)	 This Agreement contains the entire understanding of the parties about the subject matter herein and supersedes all previous agreements.

  

	 	(d)	 The parties may modify or amend the provisions hereof only by an instrument in writing duly executed by both of the parties.

  

	 	(e)	 Neither party may assign or otherwise transfer its rights or obligations hereunder without the prior written consent of the other party.

  

	 	(f)	 This Agreement may be signed by facsimile or in two counterparts, each of which when executed and delivered or transmitted, will be considered an
original and both of which together will constitute one and the same instrument. 

  

	 	(g)	 The “Background” section of this document is expressly incorporated into the Agreement. 

IN WITNESS WHEREOF the duly authorized representatives of the parties have executed this Agreement. 

 

					
	PATHEON PHARMACEUTICALS INC	 		 	POZEN INC.
			
	/s/ Dean Wilson        	 		 	/s/ John R. Plachetka        
	 Name: Dean Wilson

Title: VP Corporate Controller
	 		 	 Name: John R. Plachetka, Pharm.D.
 Title: President & Chief Executive Officer

 SCHEDULE A 

 

			
	 Pozen Funded Capital
	  	 
	
Dedicated Equipment
	  	            Cost  
          
	
Miscellaneous Screens and cloth Items
	  	$***
	
Compression tooling
	  	$***
	
Coating support equipment
	  	$***
	
Packaging Change parts
	  	$***
	
Printer Change parts
	  	$***
	
Subtotal Dedicated Equipment
	  	***
	 	 
	 	  	 
	
Non-Dedicated Equipment
	  	 
	
Blending vacuum charging
	  	***
	 Water
activity equipment
	  	***
	
***
	  	***
	
Process Engineering and Qualification
	  	***
	
***
	  	***
	
Subtotal Non-Dedicated Equipment
	  	***
	 	 
	 	  	 
	
Subtotal Equipment
	  	***
	 	 
	 	  	 
	
Facility Modifications
	  	 
	
Facility
	  	***
	
Facility Engineering and Qualification
	  	***
	
***
	  	***
	
Subtotal Facility Modifications
	  	***
	 	 
	 	  	 
	 Total
Pozen Funded Capital
	  	***
	 	 
	 	  	 
	
Patheon Funded Capital
	  	Cost
	
HPLC
	  	***
	
Dissolution Bath
	  	***
	
Subtotal Patheon Funded Capital
	  	***
	 	 
	 	  	 
	 Grand
Total Capital
	  	***EX-10.1

 Exhibit 10.1 
 AMENDMENT NO. 1 
 TO 

SEPARATION AGREEMENT OF TRUDY F. SULLIVAN 
 THIS AMENDMENT NO. 1 (this “Amendment”), dated as of June 29, 2012, to the Separation Agreement dated December 4, 2011, (the “Separation Agreement”), by and
between The Talbots, Inc., a Delaware corporation (the “Company”), and Trudy F. Sullivan (the “Executive”). 
 WHEREAS, the Executive is the President and Chief Executive Officer of the Company; 
 WHEREAS, the Executive is a party to an employment agreement with the Company, dated as of June 28, 2007, as amended (the “Employment Agreement”); 

WHEREAS, pursuant to Section 1 of the Separation Agreement, the Executive’s employment with the Company will terminate on the
date that the Company’s Board of Directors (the “Board”) appoints a successor President and Chief Executive Officer, or such earlier date as the Board shall determine, which in either case shall be no later than June 30,
2012; and 
 WHEREAS, the Company and the Executive have mutually agreed to amend Section 1 of the Separation Agreement.

 NOW, THEREFORE, in consideration of the mutual covenants and promises contained herein and other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged by the parties hereto, the parties agree as follows: 

1. Capitalized terms in this Amendment have the meanings defined in the Separation Agreement. 

2. Section 1 of the Separation Agreement is amended by deleting Section 1 and inserting the following new Section 1:

 “1. Cessation of Employment Relationship. 

The employment of the Executive with the Company will terminate (i) on the date that is next following the “Merger Closing
Date” (as such term is defined in that certain Agreement and Plan of Merger, dated as of May 30, 2012, as entered into by and among TLB Holdings, LLC, TLB Merger Sub, Inc. and The Talbots, Inc. (the “Merger Agreement”)),
or (ii) in the event that the Merger Agreement terminates without the occurrence of the Merger Closing (as such term is defined in the Merger Agreement), on such date as the Board shall determine, which shall be no later than February 2,
2013 (such date, the “Termination Date”). From the date hereof until the Termination Date, the Executive shall continue to serve as the Company’s President and Chief Executive Officer. On the Termination Date, the Executive
shall resign from all positions and directorships with the Company and any affiliate of the Company.” 

 3. It is the parties’ intent that the payments to be made to the Executive under the
Separation Agreement will, to the full extent permitted, satisfy the requirements of the short-term deferral rule exemption under Treas. Reg. Sec. 1.409A-1(b)(4) and/or the separation pay plan exception under Treas. Reg. Sec. 1.409A-1(b)(9)(iii).

 4. This Amendment may be executed in counterparts, each of which shall be deemed an original but all of which taken together
will constitute one instrument. 
 5. This Amendment embodies the entire agreement and understanding of the parties with respect
to the subject matter hereof and supersedes any and all prior agreements, arrangements and understandings, written or oral, relating to the matters provided for herein, provided, however, that the parties hereto agree that except as
expressly modified by this Amendment, all terms and provisions of the Separation Agreement and the Employment Agreement and all the respective rights and obligations of the parties to the Separation Agreement and Employment Agreement shall continue
unchanged and in full force and effect. 
 IN WITNESS WHEREOF, the parties have duly executed this Amendment as of the date
first written above. 
  

					
		 		 	            THE TALBOTS, INC.
			
	 /s/ Trudy F. Sullivan
	 		 	 /s/ Richard T. O’Connell, Jr.

	TRUDY F. SULLIVAN	 		 	Name: Richard T. O’Connell, Jr.
		 		 	Title:   Executive Vice President
	Dated: June 29, 2012	 		 	
		 		 	Dated: June 29, 2012
		 		 	

  
 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00205-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00205-of-00352.parquet"}]]